STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis
The FDA delayed its decision on a gene therapy for Duchenne muscular dystrophy and is leaning toward clearing it for only a subset of younger kids.
Oh, what a beautiful morning. Yes, this is a cliché, but the saying is apt, given the crystal clear blue skies and deliciously cool breezes enveloping the Pharmalot campus. This is also perfect hunting weather for
